Video

Dr. Bauml Discusses Biomarkers in Head and Neck Cancer

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses biomarker development for patients with head and neck cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses biomarker development for patients with head and neck cancer.

Both pembrolizumab (Keytruda) and nivolumab (Opdivo) are FDA approved for the treatment of patients with head and neck cancer, says Bauml, and are being used in a biomarker-agnostic fashion. The benefit for nivolumab is higher for patients with PD-L1—positive disease.

The FDA granted accelerated approval to pembrolizumab in August 2016 based on the objective response rates (ORR) of the phase Ib KEYNOTE-012 study. The ORR with pembrolizumab was 16% (95% CI, 11%-22%), which included a complete response rate of 5%. Responses lasted for ≥6 months for 82% of patients.

The FDA approved nivolumab in November 2016 based on the CheckMate-141 study. The median overall survival with nivolumab was 7.5 months compared with 5.1 months with investigator’s choice (HR, 0.70; 95% CI, 0.52-0.92; P = .0101). The objective response rate (ORR) was 13.3% with nivolumab and 5.8% for investigator's choice.

According to Bauml, if agents are given in combination, better biomarkers are needed to determine which patients should receive it.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity